Company intelligence / Profile preview
Leman Biotech
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
Overview
The company’s lead program, Meta10‑19 metabolically armed CD19 CAR‑T therapy, has entered investigator‑initiated clinical trials for relapsed/refractory indolent B-cell non-Hodgkin lymphoma and recurrent/refractory lymphoma. Early results suggest promise at low doses. Their IL‑10/Fc fusion protein has shown up to a ~90% cure rate in preclinical studies.
No active industry-sponsored trials are currently listed on ClinicalTrials.gov as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapies (CAR-T)Protein drugs (e.g., IL-10/Fc fusion protein)Metabolic immunotherapies
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Leman Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leman Biotech.